Time filter

Source Type

Cambridge, MA, United States

Chon J.H.,PERCIVIA | Zarbis-Papastoitsis G.,Eleven Biotherapeutics
New Biotechnology | Year: 2011

Sales of monoclonal antibody (mAbs) therapies exceeded $ 40 billion in 2010 and are expected to reach $ 70 billion by 2015. The majority of the approved antibodies are targeting cancer and autoimmune diseases with the top 5 grossing antibodies populating these two areas. In addition over 100 monoclonal antibodies are in Phase II and III of clinical development and numerous others are in various pre-clinical and safety studies.Commercial production of monoclonal antibodies is one of the few biotechnology manufacturing areas that has undergone significant improvements and standardization over the last ten years. Platform technologies have been established based on the structural similarities of these molecules and the regulatory requirements. These improvements include better cell lines, advent of high-performing media free of animal-derived components, and advances in bioreactor and purification processes. In this chapter we will examine the progress made in antibody production as well as discuss the future of manufacturing for these molecules, including the emergence of single use technologies. © 2011 Elsevier B.V. Source

There remains a substantial unmet medical need in the treatment of ocular surface inflammatory disorders, such as moderate to severe dry eye disease (DED) and allergic conjunctivitis (AC). Topical ocular IL-1 inhibition has the potential to treat the signs and symptoms of DED and treat other ocular surface inflammatory disorders such as AC. The signs and symptoms of DED are driven by different biological processes but IL-1 is a major mediator of all of these biological processes. This biological validation of IL-1 blockade in ocular surface inflammatory disorders was the basis for the engineering of EBI-005, a potent protein-based IL-1 inhibitor designed for the convenient and effective topical treatment of ocular surface inflammatory diseases such as DED and AC. © 2014 Informa UK Ltd. Source

Eleven Biotherapeutics | Date: 2014-05-02

The invention relates to methods of identifying albumin variants having improved pharmacokinetics, albumin variants having improved pharmacokinetics, and therapeutic uses of albumin variants having improved pharmacokinetics.

Eleven Biotherapeutics | Date: 2011-06-23

Disclosed herein are methods for administering an IL-1 or IL-17 antagonist for treating ocular surface disorders, e.g., a dry eye disorder. The antagonists can be administered topically using an opthalmic composition.

Eleven Biotherapeutics | Date: 2014-03-13

Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.

Discover hidden collaborations